Diabetes Mellitus Clinical Trial
Official title:
Analgesic, Antiinflammatory and Metabolic Effects of Comarum Palustre in Patients With Osteoarthritis and Diabetes Mellitus
The study evaluates analgesic, antiinflammatory and metabolic effects of Comarum palustre in patients with knee osteoarthritis (OA) and diabetes mellitus. Patients with osteoarthritis will receive Comarum palustre together with conventional treatment of osteoarthritis and diabetes.
Status | Completed |
Enrollment | 15 |
Est. completion date | November 25, 2018 |
Est. primary completion date | November 25, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: - osteoarthritis of the knee fulfilling American College of Rheumatology (ACR) criteria - diagnosis of type 2 diabetes mellitus Exclusion Criteria: - use of NSAIDs one month prior to study entry (paracetamol is allowed) - pregnancy and lactation - increased sensitivity to the study drug - clinically significant renal function impairment - use of antidepressants - diagnosis of bipolar disorder - use of symptomatic slow acting drugs of OA (SYSADOA) one month prior to study entry - any condition which may lead to difficulties to participation in the study from the viewpoint of Investigator |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Laboratory of Clinical Immunopharmacology | Novosibirsk |
Lead Sponsor | Collaborator |
---|---|
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Visual Analogue Scale for Pain | The Visual Analogue Scale for Pain varies from 0 to 10 cm. Higher values represent worse outcomes. | Baseline, 4 weeks | |
Secondary | Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Pain | KOOS Pain consists of 9 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems. | Baseline, 4 weeks | |
Secondary | Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Activities of daily living (ADL) | KOOS ADL consists of 17 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems. | Baseline, 4 weeks | |
Secondary | Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Symptoms | KOOS Symptoms consists of 7 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems. | Baseline, 4 weeks | |
Secondary | Quality of life with the The Short Form (36) Health Survey score | The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. | Baseline, 4 weeks | |
Secondary | Intermittent and Constant Osteoarthritis Pain self-report questionnaire | Pain measure: Scale range 0-100 with higher scores indicating worse pain | Baseline, 4 weeks | |
Secondary | Changes in serum levels of aggrecan | serum levels of aggrecan measured in ng/ml | Baseline, 4 weeks | |
Secondary | Changes in serum levels of antibodies to collagen type II | serum levels of antibodies to collagen type II measured AU/ml | Baseline, 4 weeks | |
Secondary | Changes in serum levels of C-reactive protein | serum levels of C-reactive protein (CRP), g/l | Baseline, 4 weeks | |
Secondary | Changes in histamine levels | serum levels of histamine in ng/ml | Baseline, 4 weeks | |
Secondary | Changes in inflammation biomarkers | serum levels of (CRP), interleukin (IL)-6, IL- 18, adiponectin, IL-10, and interferon (IFN) ? in pg/ml | Baseline, 4 weeks | |
Secondary | Changes in neopterin levels | serum neopterin measured in nmol/L | Baseline, 4 weeks | |
Secondary | Changes in lipid biomarkers | serum total cholesterol, HDL, and LDL measured in mmol/L | Baseline, 4 weeks | |
Secondary | changes in diabetes control | Glycated haemoglobin (HbA1c) | Baseline, 4 weeks | |
Secondary | Changes in depression scores measured with Patient Health Questionnaire-9 (PHQ9P) | The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. It consists of nine questions with responses ranging from "0" (not at all) to "3" (nearly every day). The possible range is 0-27. Higher values represent worse outcome. | Baseline, 4 weeks | |
Secondary | Patient global assessment of osteoarthritis | The Visual Analogue Scale for the Patient global assessment of osteoarthritis varies from 0 to 10 cm. Higher values represent worse outcomes. | Baseline, 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |